108 related articles for article (PubMed ID: 28665153)
1. Risk of peripheral edema in cancer patients treated with MEK inhibitors: a systematic review and meta-analysis of clinical trials.
Yang Y; Liu YH; Sun X; Yu MW; Yang L; Cheng PY; Yang GW; Wang XM
Curr Med Res Opin; 2017 Sep; 33(9):1663-1675. PubMed ID: 28665153
[TBL] [Abstract][Full Text] [Related]
2. Risk of selected gastrointestinal toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis.
Abdel-Rahman O; ElHalawani H; Ahmed H; Ellithy M
Expert Rev Gastroenterol Hepatol; 2015; 9(11):1433-45. PubMed ID: 26365425
[TBL] [Abstract][Full Text] [Related]
3. Risk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis.
Abdel-Rahman O; ElHalawani H; Ahmed H
Future Oncol; 2015; 11(24):3307-19. PubMed ID: 26561878
[TBL] [Abstract][Full Text] [Related]
4. Risk of Selected Cardiovascular Toxicities in Patients With Cancer Treated With MEK Inhibitors: A Comparative Systematic Review and Meta-Analysis.
Abdel-Rahman O; ElHalawani H; Ahmed H
J Glob Oncol; 2015 Dec; 1(2):73-82. PubMed ID: 28804776
[TBL] [Abstract][Full Text] [Related]
5. How to MEK the best of uveal melanoma: A systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma.
Steeb T; Wessely A; Ruzicka T; Heppt MV; Berking C
Eur J Cancer; 2018 Nov; 103():41-51. PubMed ID: 30205280
[TBL] [Abstract][Full Text] [Related]
6. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
Xu J; Tian D
Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
[TBL] [Abstract][Full Text] [Related]
7. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients.
Daud A; Gill J; Kamra S; Chen L; Ahuja A
J Hematol Oncol; 2017 Jan; 10(1):3. PubMed ID: 28052762
[TBL] [Abstract][Full Text] [Related]
8. Improved survival with MEK inhibition in BRAF-mutated melanoma.
Flaherty KT; Robert C; Hersey P; Nathan P; Garbe C; Milhem M; Demidov LV; Hassel JC; Rutkowski P; Mohr P; Dummer R; Trefzer U; Larkin JM; Utikal J; Dreno B; Nyakas M; Middleton MR; Becker JC; Casey M; Sherman LJ; Wu FS; Ouellet D; Martin AM; Patel K; Schadendorf D;
N Engl J Med; 2012 Jul; 367(2):107-14. PubMed ID: 22663011
[TBL] [Abstract][Full Text] [Related]
9. Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.
Faghfuri E; Nikfar S; Niaz K; Faramarzi MA; Abdollahi M
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):317-330. PubMed ID: 29363351
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of selumetinib compared with current therapies for advanced cancer: a meta-analysis.
Shen CT; Qiu ZL; Luo QY
Asian Pac J Cancer Prev; 2014; 15(5):2369-74. PubMed ID: 24716986
[TBL] [Abstract][Full Text] [Related]
11. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
12. Risk of Ophthalmic Adverse Effects in Patients Treated with MEK Inhibitors: A Systematic Review and Meta-Analysis.
Alves C; Ribeiro I; Penedones A; Mendes D; Batel Marques F
Ophthalmic Res; 2017; 57(1):60-69. PubMed ID: 27404571
[TBL] [Abstract][Full Text] [Related]
13. MEK and the inhibitors: from bench to bedside.
Akinleye A; Furqan M; Mukhi N; Ravella P; Liu D
J Hematol Oncol; 2013 Apr; 6():27. PubMed ID: 23587417
[TBL] [Abstract][Full Text] [Related]
14. MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors.
Grimaldi AM; Simeone E; Festino L; Vanella V; Strudel M; Ascierto PA
Am J Clin Dermatol; 2017 Dec; 18(6):745-754. PubMed ID: 28537004
[TBL] [Abstract][Full Text] [Related]
15. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
[TBL] [Abstract][Full Text] [Related]
16. Prospects for MEK inhibitors for treating cancer.
Martin-Liberal J; Lagares-Tena L; Larkin J
Expert Opin Drug Saf; 2014 Apr; 13(4):483-95. PubMed ID: 24597490
[TBL] [Abstract][Full Text] [Related]
17. Ocular Toxicities of MEK Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
Han J; Chen J; Zhou H; Hao L; Wang Q
Oncology (Williston Park); 2023 Mar; 37(3):130-141. PubMed ID: 36961957
[TBL] [Abstract][Full Text] [Related]
18. Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas.
Roskoski R
Pharmacol Res; 2017 Mar; 117():20-31. PubMed ID: 27956260
[TBL] [Abstract][Full Text] [Related]
19. Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF/MEK inhibitors in cancer patients: a meta-analysis.
Peng L; Wang Y; Hong Y; Ye X; Shi P; Zhang J; Zhao Q
Oncotarget; 2017 Oct; 8(47):83280-83291. PubMed ID: 29137342
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy of BRAF inhibitors for advanced melanoma with BRAF V600 mutation: a systematic review and meta-analysis.
Kim S; Kim HT; Suh HS
J Dermatolog Treat; 2018 May; 29(3):314-321. PubMed ID: 28504036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
